Genelux (GNLX) vs TuHURA Biosciences (HURA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 18, 2026.
Summary
TuHURA Biosciences (HURA) has outperformed Genelux (GNLX) over the past year, losing 26.7% versus a loss of 57.7%. TuHURA Biosciences is the larger company by market cap ($112.2 million vs $109.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | GNLX | HURA |
|---|---|---|
| Share price | $2.42 | $1.76 |
| Market cap | $109.49M | $112.16M |
| 1-day change | -2.42% | -3.83% |
| YTD return | -44.50% | +132.50% |
| 1-year return | -57.69% | -26.67% |
| 5-year return | — | -99.89% |
| EPS (TTM) | $-0.86 | $-0.54 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $8.00K | $0 |
| Revenue growth (YoY) | 0.00% | — |
| Net income (latest FY) | $-32.15M | $-30.05M |
| Operating margin | -415175.00% | — |
| Net margin | -401812.50% | — |
| 52-week high | $8.54 | $3.43 |
| 52-week low | $2.29 | $0.41 |
| Distance from 52-week high | -71.65% | -48.69% |
| Analyst consensus | none | none |
| Avg. price target upside | +678.10% | +356.82% |
| Average volume | 288.93K | 221.74K |
| Shares outstanding | 45.25M | 63.73M |
| Employees | 25 | 22 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- HURA has outperformed GNLX by 31.0 percentage points over the past year.
About Genelux
GNLX stock →Genelux Corporation, a clinical-stage biopharmaceutical company, focuses on developing oncolytic viral immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Its lead product candidate is Olvi-Vec (olvimulogene nanivacirepvec), a proprietary modified strain of the vaccinia virus indicated for the treatment of ovarian cancer.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
About TuHURA Biosciences
HURA stock →TuHURA Biosciences, Inc., a clinical stage immuno-oncology company, that develops novel technologies for the treatment of cancer immunotherapies. The company's lead product candidate includes IFx2.0, an innate immune agonist designed to overcome primary resistance to checkpoint inhibitors.
Health Care · Biotechnology: Pharmaceutical Preparations · 22 employees
GNLX vs HURA FAQ
Which is bigger, Genelux or TuHURA Biosciences?
TuHURA Biosciences (HURA) is larger, with a market capitalization of $112.16M compared with $109.49M for Genelux (GNLX).
Which stock has performed better over the past year, GNLX or HURA?
HURA returned -26.67% over the past 12 months, compared with -57.69% for GNLX (price return, excluding dividends). Past performance does not predict future results.
Are Genelux and TuHURA Biosciences in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.